Thermo Fisher Scientific Inc. (NYSE:TMO) Stock Holdings Decreased by Strategic Capital Advisers Inc.

Strategic Capital Advisers Inc. reduced its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 6.7% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 1,049 shares of the medical research company’s stock after selling 75 shares during the quarter. Strategic Capital Advisers Inc.’s holdings in Thermo Fisher Scientific were worth $305,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Ipswich Investment Management Co. Inc. lifted its stake in Thermo Fisher Scientific by 0.5% in the second quarter. Ipswich Investment Management Co. Inc. now owns 7,773 shares of the medical research company’s stock valued at $2,283,000 after acquiring an additional 35 shares during the last quarter. Karp Capital Management Corp lifted its stake in shares of Thermo Fisher Scientific by 0.7% in the third quarter. Karp Capital Management Corp now owns 4,980 shares of the medical research company’s stock worth $1,451,000 after buying an additional 35 shares during the last quarter. Brandywine Oak Private Wealth LLC lifted its stake in shares of Thermo Fisher Scientific by 2.0% in the third quarter. Brandywine Oak Private Wealth LLC now owns 1,813 shares of the medical research company’s stock worth $528,000 after buying an additional 36 shares during the last quarter. Landmark Bank lifted its stake in shares of Thermo Fisher Scientific by 0.3% in the third quarter. Landmark Bank now owns 13,623 shares of the medical research company’s stock worth $3,968,000 after buying an additional 40 shares during the last quarter. Finally, Arvest Bank Trust Division increased its position in Thermo Fisher Scientific by 2.8% during the third quarter. Arvest Bank Trust Division now owns 1,454 shares of the medical research company’s stock worth $424,000 after acquiring an additional 40 shares during the period. 88.24% of the stock is currently owned by institutional investors and hedge funds.

In related news, Director Jim P. Manzi sold 1,833 shares of the stock in a transaction that occurred on Thursday, August 15th. The stock was sold at an average price of $272.93, for a total transaction of $500,280.69. Following the completion of the sale, the director now directly owns 28,592 shares of the company’s stock, valued at approximately $7,803,614.56. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Marc N. Casper sold 47,729 shares of the stock in a transaction that occurred on Friday, October 25th. The stock was sold at an average price of $295.88, for a total value of $14,122,056.52. Following the sale, the chief executive officer now directly owns 328,960 shares of the company’s stock, valued at $97,332,684.80. The disclosure for this sale can be found here. Insiders sold a total of 51,833 shares of company stock worth $15,299,095 over the last quarter. 0.45% of the stock is currently owned by corporate insiders.

Shares of NYSE:TMO traded down $1.45 during mid-day trading on Monday, reaching $293.20. The stock had a trading volume of 448,030 shares, compared to its average volume of 1,323,858. The firm has a market cap of $117.34 billion, a PE ratio of 26.37, a price-to-earnings-growth ratio of 1.90 and a beta of 1.14. The firm has a 50 day simple moving average of $290.14 and a two-hundred day simple moving average of $283.57. The company has a current ratio of 1.80, a quick ratio of 1.23 and a debt-to-equity ratio of 0.56. Thermo Fisher Scientific Inc. has a twelve month low of $208.34 and a twelve month high of $306.00.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $2.94 earnings per share for the quarter, beating analysts’ consensus estimates of $2.88 by $0.06. The business had revenue of $6.27 billion for the quarter, compared to the consensus estimate of $6.19 billion. Thermo Fisher Scientific had a net margin of 14.24% and a return on equity of 17.16%. Thermo Fisher Scientific’s revenue for the quarter was up 5.9% on a year-over-year basis. During the same period last year, the company posted $2.62 EPS. On average, equities analysts anticipate that Thermo Fisher Scientific Inc. will post 12.33 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Wednesday, January 15th. Investors of record on Tuesday, December 17th will be given a $0.19 dividend. This represents a $0.76 dividend on an annualized basis and a dividend yield of 0.26%. Thermo Fisher Scientific’s dividend payout ratio is 6.83%.

Several equities research analysts have issued reports on the stock. JPMorgan Chase & Co. boosted their price target on shares of Thermo Fisher Scientific from $315.00 to $330.00 and gave the company an “overweight” rating in a report on Wednesday, October 23rd. Credit Suisse Group reaffirmed a “buy” rating and issued a $310.00 target price on shares of Thermo Fisher Scientific in a report on Wednesday, July 31st. ValuEngine lowered shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a report on Wednesday, October 2nd. Barclays set a $330.00 target price on shares of Thermo Fisher Scientific and gave the stock a “buy” rating in a report on Monday, July 15th. Finally, Needham & Company LLC upped their target price on shares of Thermo Fisher Scientific from $315.00 to $321.00 and gave the stock a “buy” rating in a report on Thursday, July 25th. One equities research analyst has rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $314.45.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Read More: What is the Current Ratio?

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.